Philippe van Holle
Geen lopende functies
Profiel
Philippe van Holle is the founder of Amsterdam Molecular Therapeutics (AMT) Holding NV, which was founded in 1998.
He held the title of Member-Supervisory Board from 2010 to 2013.
Mr. van Holle's former jobs include being an Independent Director at Argos Therapeutics, Inc. from 2015 to 2016, and being the President of Celgene International SARL from 2005 to 2014.
He also held the title of Principal at Amgen Europe BV.
Mr. van Holle received an MBA from Cornell University and an undergraduate degree from the University of Antwerp in 1976.
Eerdere bekende functies van Philippe van Holle
Bedrijven | Functie | Einde |
---|---|---|
ARGOS THERAPEUTICS, INC. | Directeur/Bestuurslid | 13-12-2016 |
Celgene International SARL
Celgene International SARL Pharmaceuticals: MajorHealth Technology Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the company is based in Boudry, Switzerland. | President | 01-10-2014 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Oprichter | 11-03-2013 |
Amgen Europe BV
Amgen Europe BV Medical DistributorsDistribution Services Part of Amgen, Inc., Amgen Europe BV wholesales pharmaceutical products. The company is based in Breda, Netherlands. | Corporate Officer/Principal | - |
Opleiding van Philippe van Holle
Cornell University | Masters Business Admin |
University of Antwerp | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Celgene International SARL
Celgene International SARL Pharmaceuticals: MajorHealth Technology Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the company is based in Boudry, Switzerland. | Health Technology |
Amgen Europe BV
Amgen Europe BV Medical DistributorsDistribution Services Part of Amgen, Inc., Amgen Europe BV wholesales pharmaceutical products. The company is based in Breda, Netherlands. | Distribution Services |
Argos Therapeutics, Inc.
Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |